APA (7th ed.) Citation

Tsimberidou, A. M., Vining, D. J., Arora, S. P., de Achaval, S., Larson, J., Kauh, J., . . . Kaseb, A. O. (2025). Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clinical cancer research, 31(6), 965-974. https://doi.org/10.1158/1078-0432.CCR-24-2920

Chicago Style (17th ed.) Citation

Tsimberidou, Apostolia M., et al. "Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors." Clinical Cancer Research 31, no. 6 (2025): 965-974. https://doi.org/10.1158/1078-0432.CCR-24-2920.

MLA (9th ed.) Citation

Tsimberidou, Apostolia M., et al. "Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors." Clinical Cancer Research, vol. 31, no. 6, 2025, pp. 965-974, https://doi.org/10.1158/1078-0432.CCR-24-2920.